| | Requirement |
| 1 | M1A or B NSCLC or any stage SCLC with any number of prior therapies |
| 2 | Planned systemic therapy |
| 3 | At least 18 years of age |
| 4 | Measurable or evaluable disease |
| 5 | ECOG performance status of 0-2 |
| 6 | Expected survival at least 3 months |
| 7 | Tumor specimens: [a] First Priority: availability of a minimum of a 1 X 10 mm core fresh frozen tumor from clinically indicated interventional procedures, with no systemic anti-cancer therapy or radiation to the biopsy site between collection of the biopsy and entry into the study; OR [b] Second Priority: availability of paraffin-embedded tumor at least 5 X 5 mm cross-sectional tumor area, with no systemic anti-cancer therapy or radiation to the biopsy site between collection of the biopsy and entry into the study; the collection of the paraffin-embedded tissues may have taken place up to 12 months prior to enrollment in CASTLE. |
| 8 | Willingness to undergo all study collection procedures and sample analyses |
| 9 | Provision of written informed consent for biospecimen storage, broad genetic and proteomic analysis of tumor and normal tissues, without restrictions, AND correlation with outcome data. |
| 1 | Other co-existing malignancies, except for basal cell carcinoma or cervical cancer in-situ |
| 2 | Compromise of patient diagnosis or staging if tissue is harvested for research |
